ReviewDrug design, development and therapy2026
Inhalation: A Smart Strategy and Increasing Potential for Drug Delivery.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The delivery of inhaled drugs is a critical and evolving strategy in modern medicine that offers distinct advantages over other routes of administration. Compared to traditional methods such as oral, intravenous, or transdermal delivery, inhalation provides rapid onset, high local drug concentrations, reduced systemic side-effects, and improved patient compliance. In addition to its established use for the treatment of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), recent technological advancements have expanded its application in systemic therapies, vaccines, and biologics. Innovative devices like dry powder inhalers, soft mist inhalers, and smart inhalers, integrated with digital health technologies, enable precise dosing, adherence monitoring, and potential personalization of therapy. Emerging trends, such as inhaled nanoparticles, gene and RNA therapies, and inhaled vaccines, have redefined the landscape of inhalation drug delivery. Despite these advances, challenges remain in terms of formulation stability, device compatibility, interpatient variability, and environmental concerns related to propellants. Future research should emphasize green technologies, integration with telehealth, patient-specific inhaler matching, and broader therapeutic applications beyond pulmonary diseases. As device engineering, digital health, and biopharmaceutical research converge, inhalation therapy has become an essential component of precision and patient-centric medicine, providing new avenues for disease treatment and prevention under both local and systemic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.